Abeona Therapeutics Inc (NASDAQ:ABEO) gapped up prior to trading on Wednesday . The stock had previously closed at $3.65, but opened at $3.50. Abeona Therapeutics shares last traded at $4.02, with a volume of 2,667,969 shares.
A number of equities analysts have recently weighed in on ABEO shares. Mizuho reissued a “hold” rating and issued a $4.00 price target on shares of Abeona Therapeutics in a report on Tuesday, December 10th. Leerink Swann started coverage on Abeona Therapeutics in a report on Monday, February 10th. They issued a “buy” rating and a $6.00 price target for the company. HC Wainwright started coverage on Abeona Therapeutics in a report on Tuesday, January 21st. They issued a “buy” rating and a $11.00 price target for the company. Svb Leerink started coverage on Abeona Therapeutics in a report on Monday, February 10th. They issued an “outperform” rating and a $6.00 price target for the company. Finally, ValuEngine raised Abeona Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Abeona Therapeutics currently has a consensus rating of “Buy” and an average target price of $7.18.
The stock has a market capitalization of $208.71 million, a price-to-earnings ratio of -2.53 and a beta of 2.16. The company has a 50 day moving average of $2.73 and a 200 day moving average of $2.70. The company has a quick ratio of 2.45, a current ratio of 2.45 and a debt-to-equity ratio of 0.07.
In other Abeona Therapeutics news, Director Stefano Buono bought 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was purchased at an average cost of $2.50 per share, for a total transaction of $500,000.00. Following the completion of the purchase, the director now owns 270,000 shares of the company’s stock, valued at approximately $675,000. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 33.60% of the company’s stock.
Large investors have recently made changes to their positions in the business. Barclays PLC increased its stake in Abeona Therapeutics by 123.5% during the third quarter. Barclays PLC now owns 57,704 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 31,883 shares during the last quarter. State Street Corp increased its stake in Abeona Therapeutics by 3.7% during the third quarter. State Street Corp now owns 635,774 shares of the biopharmaceutical company’s stock worth $1,437,000 after acquiring an additional 22,801 shares during the last quarter. Rhumbline Advisers increased its stake in Abeona Therapeutics by 9.0% during the third quarter. Rhumbline Advisers now owns 50,854 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 4,202 shares during the last quarter. Vanguard Group Inc. increased its stake in Abeona Therapeutics by 11.8% during the second quarter. Vanguard Group Inc. now owns 1,828,699 shares of the biopharmaceutical company’s stock worth $8,742,000 after acquiring an additional 193,618 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in Abeona Therapeutics during the third quarter worth about $86,000. Institutional investors own 59.98% of the company’s stock.
About Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company’s lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
